Collectively, our data suggest that frugoside treatment results in the reduction of tumorigenic ability in vitro and in vivo through intracellular ROS accumulation by inhibiting Srx protein expression and Prx hyperoxidation in melanoma cells (Figure 6E). The gene discussed is PRX; the disease is melanoma.